We have heard a lot about treatment with checkpoint inhibitors over the past two or three years. When they work well, they can work very well indeed, but these drugs come with significant risk for side effects, and some of those side effects can be very serious. … READ MORE …
Filed under: Uncategorized | Tagged: checkpoint, CTLA4, immunotherapy, inhibition, PD-1, PD-L1, risk | 1 Comment »
A newly published paper by an international group of investigators has given us some further insight in to the roles of immunotherapeutic agents in the treatment of at least a subset of men with advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: defect, immunotherapy, mismatch, nivolumab, PD-1, pembrolizumab, repair | Leave a comment »
A new review article has just been published in the journal Critical Reviews in Hematology Oncology. It is probably a current “must read” for support group leaders and for any patients who are interested in the idea of using immunotherapy as a treatment for progressive and advanced forms of prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: immunotherapy, review | Leave a comment »
In a newly published article on the STAT web site, two clinicians at Oregon Health and Science University argue that the benefits of immunotherapy in the treatment of cancer are being greatly over-“hyped”. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, hype, immunotherapy, safety | 2 Comments »
Your sitemaster is gradually “coming back to life” after a rather unpleasant week that included his trip to the GU Cancers Symposium (when he should probably have been in his bed at home). So here is the quick summary from Orlando. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active, Cancers, genitourinary, immunotherapy, surveillance | 3 Comments »
The Society for Immunotherapy of Cancer has just issued a detailed statement on the role of immunotherapy in the management of prostate cancer. The full text of this article by McNeel et al. is available on line. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: guidelines, immunotherapy, Prostvac, Provenge, sipuleucel-T | 3 Comments »
A newly published article in the journal Science Translational Medicine has questioned the merits of treating prostate cancer patients with immunotherapies while they are simultaneously being treated with medical forms of castration (androgen deprivation therapy or ADT), chemotherapy, and/or radiation therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, benefit, chenotherapy, combination, immunotherapy, radiation, risk, timing | 6 Comments »
Many readers of this blog will be aware of the development of immunotherapies like sipuleucel-T (Provenge), CAR-T for the treatment of leukemias, and checkpoint inhibitors in the treatment of some forms of solid tumor (lung cancers, melanoma). … READ MORE …
Filed under: Drugs in development | Tagged: development, drug, immunotherapy, neoantigen | Leave a comment »
There appears to be a high degree of confidence that Barvarian Nordic’s Prostvac will show positive results in the ongoing Phase III clinical trial in men with metastatic, castration-resistant prostate cancer. An early stage trial has now been initiated among men with much less advanced disease disease. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: active surveillance, immunotherapy, Prostvac, trial | 5 Comments »
A number of readers will probably be interested in reading at least part of an interview with Dr. Susan Slovin of the Memorial Sloan Kettering Cancer Center that has just been published on the CancerNetwork web site. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: immunotherapy | Leave a comment »
Starting today, we have a new contributor to the content of The “New” Prostate Cancer InfoLink. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: immunotherapy, radiation, radio-immunotherapy | 9 Comments »
Back in September 2011, a company called Advantagene initiated a randomized, placebo-controlled, Phase III clinical trial (the PrKT01 trial) of an immunotherapeutic agent known as AdV-tk, together with with standard external beam radiation therapy, in highly-defined patients with newly diagnosed, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: AdV-tk, immunotherapy, localized, radiation, trial | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 